^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
Published date:
04/14/2021
Excerpt:
Among 4271 patients receiving I-O plus chemotherapy,...OS benefit appeared to be greatest in the ≥50 % tumor PD-L1 expression group of the non-squamous cohort.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.lungcan.2021.04.007
Source:
Title:
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
Published date:
04/14/2021
Excerpt:
Among 3041 patients receiving I-O monotherapy, median OS was 11.3 (95 % CI, 9.8-12.8) months in patients with squamous NSCLC (n=875) and 14.1 (95 % CI, 12.4-15.8) months in those with non-squamous disease (n=2166). OS benefit appeared to be greatest in the ≥50 % tumor PD-L1 expression group of the non-squamous cohort.
DOI:
10.1016/j.lungcan.2021.04.007
